We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.57% | 14.50 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 1,310,616 | 10:04:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.74 | 37.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/3/2024 08:37 | “Time to move on” indeed Bones. If I valued a share at 4p and could sell for 14.75p I’d definitely move on, as opposed to coming on every couple of days saying they’ll be a raise. | adw198 | |
14/3/2024 08:20 | You’re giving her too much credit amt. Don't be daft, Bones can’t read 🤣 | paul planet earth 1 | |
14/3/2024 07:35 | Lies, lies, and more dammed lies! | bones699 | |
14/3/2024 07:34 | What nonsense Bones, why don't you read the updates which clearly state the extension of the cash runway to Q2 2025 | amt | |
14/3/2024 07:32 | Think I have more chance of spotting a unicorn walking down Croydons high street than this tu@d of a share ever turning into a pearl overnight... An inevitable cash raise on the horizon and having held for over 10 years at 40p think that's just chucking money down the u bend! No commercial deals and an unapproved product good for only testing 4% of cancers, that no ones wants, and down £130m to date sums it all up...the 'King Dog Tu@d' of all shares with a compulsive lying CEO at the helm, typical AIM stock, time to move on! | bones699 | |
12/3/2024 21:23 | Cash must be down to I reckon £7m now burning through over a £1m a month can't last long...Looking forward to Newlands 'strategic'initiativ | bones699 | |
12/3/2024 21:21 | Yup definitely on the cards...but at what price? | bones699 | |
12/3/2024 19:40 | I hear a placing is on the way. | havinthelasttoast | |
12/3/2024 18:06 | Seems nobody wants our Parsortix machines sales to date zero! ..😟😩 | bones699 | |
12/3/2024 18:05 | 13p placing is that for the whole firm seems generous wouldn't give 3p for this utter cr@p! | bones699 | |
12/3/2024 16:05 | Right back on resistance level again. Strong BUY for the next bounce. ....or TAKEOVER | philjeans | |
12/3/2024 11:21 | Looks like youre doing the rounds with your placing comments | zeus19 | |
12/3/2024 10:54 | Placing 13p | beatme1 | |
12/3/2024 10:28 | Looking like a rally coming here | kirk 6 | |
12/3/2024 09:38 | As less than 20% of shares are declared held above 3%...it makes one wonder where all those traded shares over the last few months, have gone... Curious...anyone come across any Funds / Investment Trusts that have an AGL holding...? | sawney | |
11/3/2024 20:25 | Thank you both for the feedback. I am pleased for your mate Goose and for sure, he is a classic example of the need! Let’s look forward to a successful outcome. | digger18 | |
11/3/2024 20:14 | Great and thought provoking post Gooosed. As IG said to me after the presentation, it’s about getting the best results from the samples. It is important they identify the optimal processes for doing this. The company has now brought the Illumina & Thermo Fisher NGS platforms “in house”. They had previously outsourced the samples for analysis but, according to IG, the BiDetect results were so good they brought the kits in house Dec 2023/Jan 2024. Hopefully this will help expedite future analysis of the samples. | radderssandy | |
11/3/2024 19:38 | digger18 - I suspect there are more than a few that share your disappointment but that are equally appreciative of some of the posters here - amongst so much repetitive dross. A close buddy of mine lost his wife a few years ago. A few months later he was diagnosed with Prostate cancer. He had the SoC biopsy which resulted in him being rendered impotent. The treatment however, despite what his consultant described as a serious case, was (touch wood) successful. He went on to meet (six months into the pandemic) a lovely lady who made him happy & was able to see beyond the obvious physical consequences of the prostatectomy. The difference that a simple non-invasive (repeatable) blood draw would have made is immeasurable. Solaris Healthcare have thus far added, by my reckoning a further 175,000 patients to their client base since embarking on the collaborative trial with Angle. That's 900,000 patients/annum for whom a simple, repeatable & non-invasive procedure may be the difference between life & death and a continuing quality of life. The fact as alluded to by Raddersandy, that Solaris appear happy to wait for the process to unfold - imho, speaks volumes. | gooosed | |
11/3/2024 18:13 | Thank you radders, I guess that all makes sense but just disappointing that the time lines have slipped. However, I have confidence that they will get it right and hopefully this could lead to a game changer for diagnostic albeit time delayed through a Solaris lab. | digger18 | |
11/3/2024 09:38 | radders, Another useful, informative and balanced post. Thanks - much appreciated. | bermudashorts | |
11/3/2024 09:21 | I agree Boris, so end April with final results. | fhmktg | |
11/3/2024 08:47 | Anyone who can't except timelines and targets will slip when it comes to biotevh and biopharma Co's would probably be better off infesting in utilities.... Having said that the Co. should always keep investors up to date as best they can. | boris cobaka |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions